TY - CHAP M1 - Book, Section TI - Lung Cancer A1 - Adams, Val R. A1 - Hecht, Keith A. A2 - DiPiro, Joseph T. A2 - Yee, Gary C. A2 - Posey, L. Michael A2 - Haines, Stuart T. A2 - Nolin, Thomas D. A2 - Ellingrod, Vicki PY - 2020 T2 - Pharmacotherapy: A Pathophysiologic Approach, 11e AB - Update SummaryThe following updates were made on February 4, 2021:Nonsmall Cell Lung Cancer, Local Disease (Stages I-II): revised chemotherapy options and added osimertinib for EGFR+ diseaseNonsmall Cell Lung Cancer, Advanced (Stage IV) Disease and Relapsed Disease: added atezolizumab as option to PD-L1+ tumor section; added therapy options for MET and RET mutations in Targetable Genetic Mutation sectionSmall Cell Lung Cancer Table 146-6 and Extensive Disease section: added information about chemotherapy + durvalumab and lurbinectedin to table and text and updated second-line options for extensive disease SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1191341721 ER -